(19)
(11) EP 2 336 329 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.11.2012 Bulletin 2012/47

(45) Mention of the grant of the patent:
10.10.2012 Bulletin 2012/41

(21) Application number: 11161775.9

(22) Date of filing: 30.05.2008
(51) International Patent Classification (IPC): 
C12N 15/13(2006.01)
 A01K 67/027(2006.01)

(54)

Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenis human idiotype antibodies

Zusammensetzungen und Verfahren zur Hemmung engodener Immunglobulingene und zur Erzeugung transgener menschlicher idiotypischer Antikörper

Compositions et procédés pour inhiber des gênes d' immunoglobuline endogènes et produire des anticorps d'idiotype humain transgéniques

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 01.06.2007 US 941619 P
11.04.2008 US 44324 P

(43) Date of publication of application:
22.06.2011 Bulletin 2011/25

(60) Divisional application:
12187787.2

(62) Application number of the earlier application in accordance with Art. 76 EPC:
08769934.4 / 2152880

(73) Proprietor: Omt, Inc.
Palo Alto, CA 94303 (US)

(72) Inventor:
  • Buelow, Ronald
    Palo Alto, CA 94303 (US)

(74) Representative: Harrison Goddard Foote 
Belgrave Hall Belgrave Street
Leeds LS2 8DD
Leeds LS2 8DD (GB)


(56) References cited: : 
   
  • GORMAN S D: "RESHAPING A THERAPEUTIC CD4 ANTIBODY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 88, no. 10, 15 May 1991 (1991-05-15), pages 4181-4185, XP000368701, ISSN: 0027-8424, DOI: DOI:10.1073/PNAS.88.10.4181
  • MENDEZ M J ET AL: "FUNCTIONAL TRANSPLANT OF MEGABASE HUMAN IMMUNOGLOBULIN LOCI RECAPITULATES HUMAN ANTIBODY RESPONSE IN MICE", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 146-156, XP002067603, ISSN: 1061-4036, DOI: DOI:10.1038/NG0297-146
  • PORTEUS M H ET AL: "GENE TARGETING USING ZINC FINGER NUCLEASES", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US LNKD- DOI:10.1038/NBT1125, vol. 23, no. 8, 1 August 2005 (2005-08-01) , pages 967-973, XP002467422, ISSN: 1087-0156
  • SMITH JULIANNE ET AL: "A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences", NUCLEIC ACIDS RESEARCH, vol. 34, no. 22, December 2006 (2006-12), XP002457876, ISSN: 0305-1048
  • ZARRIN ALI A ET AL: "Antibody class switching mediated by yeast endonuclease-generated DNA breaks", SCIENCE (WASHINGTON D C), vol. 315, no. 5810, January 2007 (2007-01) , pages 377-381, XP002580717, ISSN: 0036-8075
  • GEURTS ARON M ET AL: "Knockout Rats via Embryo Microinjection of Zinc-Finger Nucleases", SCIENCE (WASHINGTON D C), vol. 325, no. 5939, July 2009 (2009-07), page 433, XP002580718, ISSN: 0036-8075
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).